World Conference on Lung Cancer | Conferences

Larotrectinib Shows Activity in Lung Cancer Harboring NTRK Gene Fusions

February 02, 2021

Larotrectinib was observed to be highly active and have a favorable safety profile in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

Repotrectinib Demonstrates Early Clinical Activity in ROS1+ Metastatic NSCLC

January 31, 2021

Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.

Maintenance Therapy With Atezolizumab Triplet Improves Survival in ES-SCLC

January 31, 2021

The combination of atezolizuma plus carboplatin and etoposide demonstrated improvement in overall survival and progression-free survival when given as maintenance therapy to patients extensive stage small cell lung cancer, according to the latest findings from the IMpower 133 trial.

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC

January 31, 2021

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.

PROs Show Adjuvant Osimertinib Maintains HRQoL in EGFR+ NSCLC

January 31, 2021

Patient-reported outcomes from the phase 3 ADAURA trial showed that adjuvant osimertinib maintained health-related quality of life compared with placebo in patients with EGFR-positive non–small cell lung cancer.

Addition of Ipilimumab to Pembrolizumab Not Additive in Frontline PD-L1–High NSCLC

January 31, 2021

Survival was not improved with the immunotherapy combination of pembrolizumab and ipilimumab in comparison with pembrolizumab monotherapy in the first-line treatment of patients with metastatic non–small cell lung cancer who had high PD-L1 expression and did not harbor EGFR or ALK aberrations, findings from the phase 3 KEYNOTE-598 trial showed.